---
title: "biote Corp. (BTMD.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BTMD.US.md"
symbol: "BTMD.US"
name: "biote Corp."
industry: "Pharmaceuticals"
datetime: "2026-05-20T14:52:54.781Z"
locales:
  - [en](https://longbridge.com/en/quote/BTMD.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BTMD.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BTMD.US.md)
---

# biote Corp. (BTMD.US)

## Company Overview

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.biote.com](https://www.biote.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: C (0.56)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 91 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -5.63% |  |
| Net Profit YoY | -25.82% |  |
| P/B Ratio | -1.38 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 77610056.23 |  |
| Revenue | 188162000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -21.36% | E |
| Profit Margin | 8.29% | B |
| Gross Margin | 68.88% | A |
| Revenue YoY | -5.63% | D |
| Net Profit YoY | -25.82% | D |
| Total Assets YoY | -27.84% | E |
| Net Assets YoY | 43.47% | A |
| Cash Flow Margin | 209.11% | B |
| OCF YoY | -5.63% | D |
| Turnover | 1.77 | A |
| Gearing Ratio | 153.86% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - biote Corp.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-5.63%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-25.82%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-1.38",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "77610056.23",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "188162000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-21.36%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "8.29%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "68.88%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-5.63%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-25.82%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-27.84%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "43.47%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "209.11%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-5.63%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "1.77",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "153.86%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 4.97 | 7/189 | 6.47 | 3.68 | 2.91 |
| PB | -1.38 | 211/189 | - | - | - |
| PS (TTM) | 0.41 | 15/189 | 0.80 | 0.52 | 0.44 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-07T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 80% |
| Hold | 1 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.05 |
| Highest Target | 4.00 |
| Lowest Target | 2.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BTMD.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BTMD.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BTMD.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BTMD.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**